The deubiquitinating enzyme USP1 modulates ERα and modulates breast cancer progression

Niu, Zhiguo; Li, Xin; Feng, Suyin; Huang, Qingsong; Zhuang, Ting; Yan, Cheng; Qian, Hui; Ding, Yinlu; Zhu, Jian; Xu, Wenrong

doi:10.7150/jca.50477



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2020; 11(23):6992-7000. doi:10.7150/jca.50477 This issue Cite

Research Paper

The deubiquitinating enzyme USP1 modulates ERα and modulates breast cancer progression

Zhiguo Niu^1,2*, Xin Li^2*, Suyin Feng^3*, Qingsong Huang², Ting Zhuang², Cheng Yan⁴, Hui Qian¹, Yinlu Ding^5✉, Jian Zhu^5,2✉, Wenrong Xu^1✉

1. Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, 212000, China.
2. Henan Key Laboratory of Immunology and Targeted Drugs, School of Laboratory Medicine, Xinxiang Medical University, 453000, China.
3. Department of Neurosurgery, Affiliated Hospital of Jiangnan University, 200 Huihe Road, Wuxi, 214000, Jiangsu, China.
4. School of Medicine, Xinxiang University, Xinxiang, 453003 Henan P.R. China.
5. Department of general surgery, the Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China, 250033.
*These authors contributed equally to this work.

Citation:

Niu Z, Li X, Feng S, Huang Q, Zhuang T, Yan C, Qian H, Ding Y, Zhu J, Xu W. The deubiquitinating enzyme USP1 modulates ERα and modulates breast cancer progression. J Cancer 2020; 11(23):6992-7000. doi:10.7150/jca.50477. https://www.jcancer.org/v11p6992.htm

Other styles

Abstract

Breast cancer is one of the most common malignancies worldwide, while the luminal types (ERα positive) accounts for two third of all breast cancer cases. Although ERα positive breast cancer could be effective controlled by endocrine therapy, most of the patients will develop endocrine resistance, which becomes a headache clinical issue for breast cancer field. Endocrine resistance could be caused by multiple pathway disorders, the dys-regulation of ERα signaling might be a critical factor, which makes it urgent and important to reveal the potential molecular mechanism of ERα signaling. In our current study, we identified a new deubiquitination enzyme USP1 through screening the whole DUB (Deubiquitinases) siRNA library. The expression of USP1 is elevated in human breast cancer compared with normal mammary tissues. Importantly, USP1 expression levels are specially correlated with poor survival in ERα positive patients. USP1 depletion inhibited breast cancer cell progression and ERα signaling activity. Immuno-precipitation assays indicate that USP1 associates with ERα and promotes its stability possibly via inhibiting ERα K48-linked poly-ubiquitination. In conclusion, our data implicate a non-genomic mechanism by USP1 via stabilizing ERα protein controls ERα target gene expression linked to breast cancer progression.

Keywords: USP1, ERα, Breast cancer, Deubiquitin, Stabilize

Citation styles

APA

Niu, Z., Li, X., Feng, S., Huang, Q., Zhuang, T., Yan, C., Qian, H., Ding, Y., Zhu, J., Xu, W. (2020). The deubiquitinating enzyme USP1 modulates ERα and modulates breast cancer progression. Journal of Cancer, 11(23), 6992-7000. https://doi.org/10.7150/jca.50477.

ACS

Niu, Z.; Li, X.; Feng, S.; Huang, Q.; Zhuang, T.; Yan, C.; Qian, H.; Ding, Y.; Zhu, J.; Xu, W. The deubiquitinating enzyme USP1 modulates ERα and modulates breast cancer progression. J. Cancer 2020, 11 (23), 6992-7000. DOI: 10.7150/jca.50477.

NLM

CSE

Niu Z, Li X, Feng S, Huang Q, Zhuang T, Yan C, Qian H, Ding Y, Zhu J, Xu W. 2020. The deubiquitinating enzyme USP1 modulates ERα and modulates breast cancer progression. J Cancer. 11(23):6992-7000.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.